Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Eisai Expands Marketing and Supply Agreement for Anti-obesity Agent Lorcaserin to Include Most Countries Worldwide



Eisai Expands Marketing and Supply Agreement for Anti-obesity Agent Lorcaserin
                     to Include Most Countries Worldwide

  PR Newswire

  HATFIELD, England, November 8, 2013

HATFIELD, England, November 8, 2013 /PRNewswire/ --

Eisai announces today that it has expanded the marketing and supply agreement
between its U.S. subsidiary Eisai Inc. and U.S-based Arena Pharmaceuticals
Inc.'s Swiss subsidiary, Arena Pharmaceuticals GmbH, for the anti-obesity
agent lorcaserin hydrochloride (lorcaserin) (U.S. brand name: BELVIQ ^® ).
Whilst the existing agreement granted Eisai Inc. exclusive rights to market
and distribute lorcaserin in 21 countries throughout the Americas, the
expanded agreement now includes most countries and territories worldwide, most
notably, the member states of the European Union, Japan and China (but
excludes South Korea, Taiwan, Australia, New Zealand and Israel).

Under this agreement, Eisai will be working in collaboration with Arena to
develop and seek marketing authorisation of lorcaserin as an anti-obesity
treatment in its territories. In addition to pursuing regulatory approval for
weight management in the expanded territories, Eisai and Arena plan to
investigate the potential of lorcaserin in new areas, such as: smoking
cessation, a once-daily formulation, a fixed-dose combination with
phentermine, as well as explore lorcaserin's impact on diabetes and
cardiovascular outcomes.

Lorcaserin is marketed in the U.S. by Eisai Inc., and is approved by the U.S.
Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and
increased physical activity for chronic weight management in adult patients
with an initial body mass index (BMI) of 30 kg/m ^2 or greater, or 27 kg/m ^2
or greater in the presence of at least one weight-related co-morbid condition.
Marketing authorization has also been applied for in Mexico and Canada.

In recent years, obesity has become a major global health problem, with more
than 1.4 billion adults worldwide believed to be overweight and approximately
500 million of that number qualifying as obese. ^[1] By region, around 170
million people in the United States ^[2] and 150 million people in Europe are
reported to be obese or overweight. ^[3] In Europe, it is estimated that
10-30% of adults are obese. ^[4]

Eisai is dedicated to discovering, developing and producing innovative
therapies that can make a difference and impact the lives of patients and
their families. This passion for people is part of Eisai's human health care
(hhc) mission, which strives for better understanding of the needs of patients
and their families to increase the benefits health care provides.

Notes to Editors

About BELVIQ ^®   (lorcaserin hydrochloride)

Discovered and developed by Arena Pharmaceuticals, Inc., lorcaserin is a new
chemical entity that is believed to decrease food consumption and promote
satiety in individuals by selectively activating serotonin 2C receptors in the
brain. Lorcaserin was launched in the United States in June 2013 after
receiving a final scheduling designation from the U.S. Drug Enforcement
Administration (DEA).

About Eisai

Eisai is one of the world's leading research and development (R&D) based
pharmaceutical companies, and we define our corporate mission as "giving first
thought to patients and their families and to increasing the benefits health
care provides," which we call human health care ( hhc ).

Eisai concentrates its R&D activities in three key areas:

  * Oncology including: anticancer therapies; tumour regression, tumour
    suppression, antibodies, etc.
  * Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight
    loss
  * Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
    arthritis, psoriasis, inflammatory bowel disease

With operations in the U.S., Asia, Europe and its domestic home market of
Japan, Eisai employs more than 10,000 people worldwide. From its EMEA
Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business
operations to include Europe, the Middle East, Africa, Russia and Oceania
(EMEA). Eisai EMEA has sales and marketing operations in over 20 markets,
including the United Kingdom, France, Germany, Italy, Spain, Switzerland,
Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Czech Republic,
Slovakia, the Netherlands, Belgium, Luxembourg, Russia and the Middle East.

For further information please visit our web site http://www.eisai.co.uk

About Arena Pharmaceuticals

Arena is a biopharmaceutical company focused on discovering, developing and
commercialising novel drugs that target G protein-coupled receptors, or GPCRs,
to address unmet medical needs. Arena's US operations are located in San
Diego, California, and its operations outside of the United States, including
its commercial manufacturing facility, are located in Zofingen, Switzerland.

For more information, visit Arena's website at http://www.arenapharm.com

Arena Pharmaceuticals ^® and Arena ^® are registered service marks of Arena
Pharmaceuticals, Inc. BELVIQ ^® is a registered trademark of Arena
Pharmaceuticals GmbH.

1. World Health Organisation. Data and statistics for Obesity. World Health
Organisation. Data and statistics for Europe.
http://www.who.int/mediacentre/factsheets/fs311/en/ [
http://www.who.int/mediacentre/factsheets/fs311/en ]. Last accessed 7 November
2013

2. American Heart Association.
http://www.heart.org/idc/groups/heart-public/@wcm/@sop/@smd/documents/downloadable/ucm_319588.pdf
. Last accessed 7 November 2013.

3. World Health Organisation. Data and statistics for Europe
http://www.euro.who.int/__data/assets/pdf_file/0008/98243/E89858.pdf . Last
accessed 7 November 2013

4. World Health Organisation. Data and statistics for Europe.
http://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity/data-and-statistics
. Last accessed 7 November 2013.

Date of preparation: November 2013        

Job code: Corporate-UK2020

Contact: Media Enquiries: Eisai Europe Ltd, Cressida Robson / Charlotte
Andrews, +44(0)7908 314 155 / +44(0)7947 231 513, Cressida_Robson@eisai.net,
Charlotte_Andrews@eisai.net. Tonic Life Communications, Siobhan Reilly / April
Kenneally, +44(0)207 798 9999 / +44(0)207 798 9263,
siobhan.reilly@toniclc.com, april.kenneally@toniclc.com.
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement